1. Korber B, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell 182, 812-827.e819 (2020).
2. Davies NG, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science (New York, NY) 372, (2021).
3. Frampton D, et al. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. The Lancet Infectious diseases, (2021).
4. Harvey WT, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nature reviews Microbiology 19, 409-424 (2021).
5. Wang P, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130-135 (2021).
6. Wibmer CK, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature medicine 27, 622-625 (2021).
7. Wu K, et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. The New England journal of medicine 384, 1468-1470 (2021).
8. Liu Y, et al. Neutralizing Activity of BNT162b2-Elicited Serum. The New England journal of medicine 384, 1466-1468 (2021).
9. Shinde V, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. The New England journal of medicine 384, 1899-1909 (2021).
10. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. The New England journal of medicine 385, 187-189 (2021).
11. Puranik A. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. MedRXiv, (2021).
12. Garçon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert review of vaccines 11, 349-366 (2012).
13. Ellebedy AH, et al. Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans. Proceedings of the National Academy of Sciences of the United States of America 117, 17957-17964 (2020).
14. Leroux-Roels I, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet (London, England) 370, 580-589 (2007).
15. Francica JR, et al. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Science translational medicine, (2021).
16. Goepfert PA, et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. The Lancet Infectious diseases, (2021).
17. Crawford KHD, et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses 12, (2020).
18. Kalnin KV, et al. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. NPJ vaccines 6, 61 (2021).
19. McCormick KD, Jacobs JL, Mellors JW. The emerging plasticity of SARS-CoV-2. Science (New York, NY) 371, 1306-1308 (2021).
20. Roy-Ghanta S, Van der Most R, Li P, Vaughn DW. Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study. The Journal of infectious diseases 210, 1419-1430 (2014).
21. Khurana S, et al. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization. NPJ vaccines 3, 40 (2018).
22. Zhong W, Levine MZ. Stockpiled Avian Influenza A(H7N9) Vaccines Induce Robust, Nonneutralizing Functional Antibodies Against Antigenically Drifted Fifth-Wave A(H7N9) Viruses. The Journal of infectious diseases 220, 1276-1280 (2019).
23. Corbett KS. Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates. bioRxiv : the preprint server for biology, (2021).
24. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 29, 2272-2278 (2011).
25. Inoue T, Moran I, Shinnakasu R, Phan TG, Kurosaki T. Generation of memory B cells and their reactivation. Immunological reviews 283, 138-149 (2018).
26. Khoury DS, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature medicine 27, 1205-1211 (2021).
27. Krammer F. Correlates of protection from SARS-CoV-2 infection. Lancet (London, England) 397, 1421-1423 (2021).
28. Earle KA, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423-4428 (2021).
29. Corbett KS, et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. The New England journal of medicine 383, 1544-1555 (2020).